Danaparoid: Difference between revisions
CSV import |
No edit summary Tag: Manual revert |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 30: | Line 30: | ||
{{stub}} | {{stub}} | ||
{{No image}} | |||
{{No image}} | {{No image}} | ||
Latest revision as of 17:19, 18 March 2025
Danaparoid is an anticoagulant medication that is used to prevent and treat thrombosis. It is a mixture of heparan sulfate, dermatan sulfate, and chondroitin sulfate, which are all glycosaminoglycans. Danaparoid is marketed under the brand name Orgaran.
Mechanism of Action[edit]
Danaparoid works by inhibiting factor Xa, a protein involved in blood clotting. It does this by enhancing the activity of antithrombin, a protein that inhibits factor Xa. This prevents the formation of blood clots.
Uses[edit]
Danaparoid is used to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also used in the treatment of heparin-induced thrombocytopenia (HIT).
Side Effects[edit]
Common side effects of danaparoid include bleeding, anemia, and thrombocytopenia. Rare but serious side effects include allergic reactions, osteoporosis, and heparin-induced thrombocytopenia (HIT).
Contraindications[edit]
Danaparoid should not be used in people with active bleeding or a history of heparin-induced thrombocytopenia (HIT). It should also not be used in people with severe kidney disease.
Interactions[edit]
Danaparoid may interact with other anticoagulants, increasing the risk of bleeding. It may also interact with certain medications used to treat heart disease and high blood pressure.
Dosage[edit]
The dosage of danaparoid depends on the condition being treated and the patient's weight. It is usually given as an injection under the skin.


